secwatch.observer — SEC 8-K summary
======================================

Issuer:     CORCEPT THERAPEUTICS INC (CORT)
CIK:        0001088856
Form:       8-K
Filed at:   2022-12-08T23:59:59+00:00
Accession:  0001193125-22-300535
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corcept settles patent litigation with Hikma; generic Korlym entry set for October 2034
--------------------------------------------------------------------------------

- Settlement with Hikma resolves patent litigation over generic Korlym in District of New Jersey.
- Hikma granted right to sell generic Korlym in U.S. beginning October 1, 2034 or earlier under customary conditions.
- Similar patent litigation against Teva Pharmaceuticals USA remains pending.
- Settlement subject to court consent judgment and FTC/DOJ review.
- CEO Belanoff noted the settlement allows focus on growing Korlym and developing cortisol modulator pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1088856/000119312522300535/0001193125-22-300535-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1088856/000119312522300535/d430330d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-300535

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer